Qu Biologics Granted Broad Australian Patent for Targeted Treatment of Multiple Cancers

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 22, 2014) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to reboot the body's immune system to treat cancer and autoimmune disease, announced it has been granted its second broad Australian patent for the targeted treatment of various cancers, including all common cancers.

Qu Biologics has been issued Australian Patent No.2007308721. The granted patent involves the tissue-targeted activation of the immune response to treat cancers. The patent encompasses formulations of killed viruses to stimulate this site specific anti-tumour immune response.

Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, "Immunotherapies represent a paradigm shift in the treatment of cancer by focusing on the immune response rather than the tumour. Qu Biologics is at the forefront of immunotherapy treatment that 'reboots' the body's innate immune system and this second broad patent allows us to protect and further extend our strong position in immunotherapy research and the development of our site specific immunomodulators."

Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are derived from inactivated bacteria and viruses aimed at stimulating the body's own immune system against cancer and autoimmune disease. The company's SSI platform represents a promising new approach to cancer and autoimmune disease. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease. The company recently launched a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn's disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information,visit www.qubiologics.com and www.qucrohnstrial.com.